Powell Investment Advisors LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 59.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,097 shares of the biopharmaceutical company’s stock after buying an additional 2,646 shares during the period. Powell Investment Advisors LLC’s holdings in Gilead Sciences were worth $438,000 at the end of the most recent quarter.
→ How the Ultra Rich Pick Their Stocks (From Vantage Point)
Other large investors also recently modified their holdings of the company. Cetera Investment Advisers lifted its stake in Gilead Sciences by 9.2% in the 1st quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock valued at $3,446,000 after purchasing an additional 4,877 shares during the last quarter. Baird Financial Group Inc. lifted its stake in Gilead Sciences by 3.9% in the 1st quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock valued at $26,660,000 after purchasing an additional 16,643 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Gilead Sciences by 44.3% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 2,654 shares during the last quarter. Donaldson Capital Management LLC lifted its stake in Gilead Sciences by 12.5% in the 1st quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 641 shares during the last quarter. Finally, Ergoteles LLC acquired a new stake in Gilead Sciences in the 1st quarter valued at about $2,304,000. 78.72% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Price Performance
NASDAQ:GILD traded down $1.17 during mid-day trading on Friday, reaching $81.37. The stock had a trading volume of 1,781,265 shares, compared to its average volume of 6,480,970. The stock has a 50-day simple moving average of $85.02 and a two-hundred day simple moving average of $76.62. The stock has a market capitalization of $102.06 billion, a PE ratio of 22.61, a P/E/G ratio of 0.99 and a beta of 0.39. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.36 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 12 month low of $57.17 and a 12 month high of $89.74.
Gilead Sciences (NASDAQ:GILD – Get Rating) last issued its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.17. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. The firm had revenue of $7.39 billion for the quarter, compared to analyst estimates of $6.63 billion. During the same quarter last year, the business posted $0.69 earnings per share. The company’s quarterly revenue was up 2.0% on a year-over-year basis. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 6.85 earnings per share for the current year.
Gilead Sciences Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Wednesday, March 15th will be given a $0.75 dividend. The ex-dividend date is Tuesday, March 14th. This represents a $3.00 dividend on an annualized basis and a yield of 3.69%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.73. Gilead Sciences’s dividend payout ratio (DPR) is currently 80.00%.
Wall Street Analyst Weigh In
GILD has been the subject of several recent analyst reports. Jefferies Financial Group raised their target price on shares of Gilead Sciences from $78.00 to $86.00 and gave the company a “buy” rating in a research note on Friday, October 28th. Maxim Group increased their price target on shares of Gilead Sciences from $84.00 to $92.00 and gave the company a “buy” rating in a report on Monday, October 31st. Royal Bank of Canada cut shares of Gilead Sciences from an “outperform” rating to a “sector perform” rating and set a $87.00 price target on the stock. in a report on Tuesday, January 3rd. Oppenheimer increased their price target on shares of Gilead Sciences from $95.00 to $105.00 in a report on Thursday, December 1st. Finally, Cowen increased their price target on shares of Gilead Sciences from $80.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, November 8th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $89.45.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Gilead Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Gilead Sciences wasn’t on the list.
While Gilead Sciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.